While most of the funding for biotech startups developing novel therapeutics has stalled in the past year as VCs take a more conservative approach and focus on companies already generating revenue through multiple streams, demand for therapies has not decreased.

Over the last decade, professionals working in the Life Sciences understand that change has been the only constant.

It wasn’t long ago when the term “artificial intelligence” (AI) conjured up images of hyper realistic human robots or flying cars.

With much of biotech news focusing on a down market and several prominent companies having recently failed to hit primary endpoints, it begs the question…